Eli Lilly Boosts Full-Year Revenue Guidance as Mounjaro and Zepbound Surge Drives $23 Billion Q2 Revenue
INDIANAPOLIS, IN : Pharmaceutical titan Eli Lilly and Company (NYSE: LLY) delivered a staggering second-quarter 2026 financial report on Wednesday, propelled by unrelenting global demand for its flagship GLP-1 and dual GIP/GLP-1 receptor agonist therapies, Mounjaro and Zepbound. The Indianapolis-based drugmaker posted quarterly revenue of $22.97 billion, representing a 48% year-over-year increase compared to the $15.56 billion reported in the second quarter of 2025.
Spurred by unprecedented volume expansion in diabetes and obesity treatments, Lilly raised its full-year 2026 revenue guidance to between $85.0 billion and $87.0 billion. The company updated its full-year non-GAAP earnings per share (EPS) forecast to $35.50 to $36.50. This range reflects an underlying operational earnings boost of $2.78 per share, offset by $3.03 per share in acquired in-process research and development (IPR&D) charges tied to aggressive second-quarter business development acquisitions.
Following the earnings announcement, Eli Lilly shares climbed nearly 5% in premarket trading to around $1,170 per share, further reinforcing its position as the world’s most valuable healthcare company with a market capitalization exceeding $1.0 trillion.
Q2 2026 Financial Highlights: Reported vs. Prior Year
+-----------------------------------------------------------------------------------+
| ELI LILLY Q2 2026 FINANCIAL SUMMARY |
+-------------------+--------------------+--------------------+---------------------+
| Financial Metric | Q2 2026 Actual | Q2 2025 Actual | YoY Change (%) |
+-------------------+--------------------+--------------------+---------------------+
| Total Revenue | $22.97 Billion | $15.56 Billion | +48% |
| Net Income (GAAP) | $7.10 Billion | $5.66 Billion | +25% |
| Diluted EPS (GAAP)| $7.94 | $6.29 | +26% |
| Non-GAAP EPS | $8.38 | $6.31 | +33% |
| Gross Margin % | 85.8% | 84.3% | +1.5 ppts |
| Operating Income | $8.98 Billion | $6.86 Billion | +31% |
+-------------------+--------------------+--------------------+---------------------+
Source: Eli Lilly and Company Q2 2026 Financial Release
Incretin Blockbusters: Mounjaro and Zepbound Lead the Charge
The primary catalyst behind Eli Lilly’s rapid revenue acceleration continues to be its incretin franchise, led by tirzepatide—marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
-
Mounjaro Sales Surge: Mounjaro generated $9.94 billion in quarterly sales alone, marking a 91% year-over-year surge compared to Q2 2025. The drug beat consensus analyst estimates by roughly 12%, driven by rapid adoption in the United States and expanded international market access, including recent inclusion on China’s National Reimbursement Drug List (NRDL). Year-to-date sales for Mounjaro have reached $18.61 billion.
-
Zepbound Acceleration: Zepbound brought in $4.93 billion during the second quarter, representing a 46% sequential and year-over-year increase as production capacity additions helped fulfill prescription demand across retail and mail-order pharmacies.
-
Emerging Oral GLP-1: Lilly’s recently launched daily oral weight-loss therapy, Foundayo, recorded $98 million in its first full quarter of commercial sales, edging out Wall Street projections of $92 million.
+-----------------------------------------------------------------------------------+
| KEY PRODUCT REVENUE BREAKDOWN (Q2 2026) |
+-------------------+--------------------+--------------------+---------------------+
| Product Name | Primary Indication | Q2 2026 Revenue | YoY Growth (%) |
+-------------------+--------------------+--------------------+---------------------+
| Mounjaro | Type 2 Diabetes | $9.94 Billion | +91% |
| Zepbound | Weight Management | $4.93 Billion | +46% |
| Verzenio | Oncology | $1.48 Billion | +11% |
| Jardiance | Diabetes / Heart | $1.02 Billion | +8% |
| Taltz | Immunology | $890 Million | +7% |
| Jaypirca | Hematology | $192 Million | +56% |
| Foundayo | Oral Obesity | $98 Million | New Launch |
+-------------------+--------------------+--------------------+---------------------+
Source: Eli Lilly Q2 2026 Earnings Data
Geographic Breakdown and Supply Chain Investments
Worldwide volume for Eli Lilly products expanded by 60% year-over-year during the second quarter.
-
U.S. Performance: Revenue in the United States reached $14.40 billion, up 33% year-over-year. Volume increased 37%, slightly offset by a 3% net decline in realized prices due to contractual channel rebates and expanding commercial insurance coverage tiering for Zepbound and Mounjaro.
-
International Expansion: Revenue outside the U.S. jumped 80% to $8.60 billion, anchored by a 113% volume surge. International growth was fueled by Mounjaro launches across Europe, Latin America, and Asia-Pacific markets.
To eliminate remaining supply bottlenecks and meet multi-year demand projections, Eli Lilly committed an additional $4.5 billion during the quarter to expand its Indiana manufacturing complexes. The capital allocation brings Lilly’s total announced manufacturing investments since 2020 to over $23 billion, covering new active pharmaceutical ingredient (API) synthesis facilities and automated pen-filling lines across North America and Europe.
Pipeline Progress: Retatrutide and Strategic M&A
In addition to commercial sales performance, Eli Lilly highlighted major advancements across its clinical pipeline and business development portfolio during the quarter:
1. Triple-G agonist Retatrutide
Lilly completed three additional Phase 3 clinical trials for retatrutide, its triple hormone receptor agonist (GIP/GLP-1/glucagon) targeting obesity, obstructive sleep apnea, and knee osteoarthritis pain. With the pivotal clinical data package now complete, Lilly announced plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first quarter of 2027.
2. Strategic M&A and Acquired IPR&D
Lilly closed several key acquisitions during Q2 to bolster its long-term oncology, genetic medicine, and immunology platforms. Completed transactions included Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics. These strategic deals resulted in $2.8 billion in upfront IPR&D charges recognized during the quarter, representing a short-term accounting drag on EPS that management views as essential for pipeline longevity.
+-----------------------------------------------------------------------------------+
| 2026 FULL-YEAR GUIDANCE UPDATES |
+-----------------------------------+--------------------+--------------------------+
| Financial Metric | Updated Guidance | Prior Guidance |
+-----------------------------------+--------------------+--------------------------+
| Full-Year Total Revenue | $85.0B – $87.0B | $82.5B – $85.0B |
| Gross Margin Percentage (Non-GAAP)| ~86.0% | ~85.5% |
| Full-Year Non-GAAP EPS | $35.50 – $36.50 | $36.00 – $37.00* |
+-----------------------------------+--------------------+--------------------------+
*Prior EPS range did not include $3.03/share in Q2 acquired IPR&D charges.
Industry Context: The Expanding Obesity Therapeutics Market
Wall Street analysts estimate that the global metabolic and obesity therapeutics market could exceed $150 billion annually by 2030. Eli Lilly and Danish rival Novo Nordisk continue to operate in a near-duopoly, scaling production as fast as possible to meet consumer demand.
Commentary from industry analysts underscores Lilly’s execution momentum. In an investor note, healthcare analysts highlighted that Eli Lilly’s total top line for the first half of 2026 alone surpassed $42 billion—nearly double the company’s full-year 2020 revenue of $24 billion. With next-generation agents like retatrutide entering regulatory review tracks, Lilly appears well-positioned to maintain its leadership in cardiometabolic medicine.
